The stock of Roivant Sciences Ltd (NASDAQ:ROIV) last traded at $11.02, down -4.34% from the previous session.
ROIV stock price is now -7.12% away from the 50-day moving average and -3.12% away from the 200-day moving average. The market capitalization of the company currently stands at $8.02B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 176,900 shares of the company’s stock on Dec 27 ’24. The stock was sold for $2,090,958 at an average price of $11.82. Upon completion of the transaction, the President & COO now directly owns 668,680 shares in the company, valued at $7.37 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 30 ’24, President & COO Venker Eric sold 177,704 shares of the business’s stock. A total of $2,050,704 was realized by selling the stock at an average price of $11.54. This leaves the insider owning 740,976 shares of the company worth $8.17 million. A total of 48.22% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $9.69 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.43, and a quick ratio of 10.43. The fifty day moving average price for ROIV is $11.8832 and a two-hundred day moving average price translates $11.3702 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for 2024-09-30. The net profit margin was 3827.42% and return on equity was 159.08% for ROIV. The company reported revenue of $4.47 million for the quarter, compared to $3.65 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.67 percent.
